7,171 Views
•
10:27 min
•
July 25, 2020
DOI:
Summary
Automatically generated
Here we present a protocol to test the efficacy of targeted therapies selected based on the genomic makeup of a tumor. The protocol describes identification and validation of structural DNA rearrangements, engraftment of patients’ tumors into mice and testing responses to corresponding drugs.
Explore More Videos
Related Videos
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Related Videos
13591 Views
07:07
A Melanoma Patient-Derived Xenograft Model
Related Videos
12268 Views
04:49
Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Related Videos
6247 Views
07:42
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Related Videos
4764 Views
09:37
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Related Videos
1710 Views
08:52
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Related Videos
3879 Views
06:59
Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
Related Videos
1078 Views
09:33
Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Related Videos
1054 Views
06:06
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Related Videos
423 Views
07:10
Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells
Related Videos
12569 Views
Read Article
Cite this Article
Zhang, P., Kovtun, I. V. Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts. J. Vis. Exp. (161), e60646, doi:10.3791/60646 (2020).
Copy